Last reviewed · How we verify

ATB-1013 — Competitive Intelligence Brief

ATB-1013 (ATB-1013) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Autotaxin inhibitor. Area: Immunology / Fibrosis.

phase 3 Autotaxin inhibitor Autotaxin (ATX) Immunology / Fibrosis Small molecule Live · refreshed every 30 min

Target snapshot

ATB-1013 (ATB-1013) — Autotelicbio. ATB-1013 is an autotaxin inhibitor that reduces lysophosphatidic acid (LPA) production to modulate immune and fibrotic responses.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ATB-1013 TARGET ATB-1013 Autotelicbio phase 3 Autotaxin inhibitor Autotaxin (ATX)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Autotaxin inhibitor class)

  1. Autotelicbio · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ATB-1013 — Competitive Intelligence Brief. https://druglandscape.com/ci/atb-1013. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: